Harbor Capital Advisors’s Krystal Biotech KRYS Stock Holding History

Harbor Capital Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,757	Closed	-$1.38M	–	750
2024 Q1	$1.38M	Buy	7,757 +1,495	+24%	+$208K	0.18%	148
2023 Q4	$777K	Buy	6,262 +1,148	+22%	+$127K	0.15%	177
2023 Q3	$593K	Sell	5,114 -1,864	-27%	-$227K	0.13%	198
2023 Q2	$819K	Buy	6,978 +595	+9%	+$60.8K	0.16%	167
2023 Q1	$511K	Sell	6,383 -2,118	-25%	-$166K	0.15%	141
2022 Q4	$673K	Sell	8,501 -3,276	-28%	-$243K	0.65%	55
2022 Q3	$821K	Sell	11,777 -1,277	-10%	-$92.3K	0.75%	43
2022 Q2	$857K	Sell	13,054 -2,251	-15%	-$140K	0.65%	48
2022 Q1	$1.02M	Sell	15,305 -3,167	-17%	-$198K	0.48%	61
2021 Q4	$1.29M	Buy	+18,472	New	+$1.08M	0.47%	62

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Harbor Capital Advisors's KRYS Position: Q2 2024 in Review

Harbor Capital Advisors sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 7,757 shares — an estimated $1.38M sold.

Harbor Capital Advisors first reported a position in KRYS in Q4 2021 and held it in 10 quarters. The position peaked at $1.38M in Q1 2024. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

Harbor Capital Advisors reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
Harbor Capital Advisors sold 7,757 Krystal Biotech shares in Q2 2024, an estimated $1.38M.
Harbor Capital Advisors first reported a position in Krystal Biotech in Q4 2021 and held it in 10 quarters.
Harbor Capital Advisors's Krystal Biotech position peaked at $1.38M in Q1 2024.
245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Harbor Capital Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.